Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more
GLP-Compliant Analytics for IND-Enabling Toxicology Studies of Viral Vectors
PROVEN INTELLIGENCE IN GXP-COMPLIANT VECTOR ANALYTICS.
GLP-Compliant Analytics for IND-Enabling Toxicology Studies of Viral Vectors
Analytics for Viral Vector IND-Enabling Toxicology
CELL & GENE | RNA | BIOLOGICS
Executive Summary
For next-generation therapeutics based on viral vectors, the analytical data package supporting IND-enabling toxicology studies is the foundation of a successful regulatory submission. Standard, non-qualified assays are insufficient for de-risking complex biology. This page details the requirement for phase-appropriate, GxP-compliant analytical methods to characterize vector identity, purity, potency, and stability in biological samples from toxicology models. We outline how this rigorous approach provides the data integrity needed for global regulatory bodies (FDA, EMA, MHRA) and directly supports an accelerated 18-24 month timeline to IND.
Frequently Asked Questions
Q: What is the difference between research-grade and GxP-compliant analytics for viral vectors?
Research-grade analytics are designed for speed and discovery, providing directional data for early-stage decisions. GxP-compliant analytics are performed in a controlled environment with qualified or validated assays, formal standard operating procedures (SOPs), and complete data traceability. This level of rigor is required for data submitted in IND-enabling toxicology reports to global regulatory agencies.
Q: Why are custom analytical assays often necessary for IND-enabling toxicology studies of novel AAV vectors?
Each AAV serotype, promoter, and transgene combination presents a unique biological profile. Pre-existing or platform assays may not accurately measure the potency, expression, or biodistribution of a novel vector. Developing custom, qualified assays ensures the data accurately reflects the test article’s specific activity and potential toxicities in vivo, which is fundamental to minimizing clinical risk.
Q: How do robust analytics support non-target tissue biodistribution assessments?
GxP-compliant quantitative methods, such as qPCR or ddPCR, are used to precisely measure vector genome copies in all relevant tissues collected from toxicology models. This provides a definitive map of where the vector distributes beyond the intended target organ. This data is a core component of the safety assessment for any IND submission and informs the design of clinical monitoring plans.
A viral vector’s performance in a preclinical model is only as reliable as the analytical methods used to measure it. For sponsors of next-generation therapeutics, the transition from research-grade characterization to a GxP-compliant analytical package is a pivotal step on the path to a successful IND submission. This process requires a scientific partner with a deep history in vector biology and regulatory compliance.
The core team at Franklin Biolabs carries a track record of a 100% successful IND rate since 2019, established prior to our formal launch in 2024. This success is built on a foundational understanding of vector analytics. As one collaborator noted, our team’s work laid the groundwork for their program: “We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies… This collaboration is central to our AAV-vector based gene therapy candidate development.”
De-Risking Clinical Translation with Phase-Appropriate Analytics
The selection of an animal model and route of administration has profound implications for the safety profile of a viral vector. Unexpected toxicities can emerge that are directly linked to these choices. For instance, preclinical work in large animals has shown that the specific intrathecal delivery route of an AAV vector can lead to significant adverse events like encephalitis, even with similar transduction efficiency (PMID: 28806897).
This finding underscores a key principle: a toxicology study’s value depends on robust bioanalytical endpoints. Without qualified assays to analyze samples for vector persistence, transgene expression, and immunogenicity, it is difficult to interpret adverse findings or confirm the mechanism of action. Our approach involves developing and qualifying assays in a phase-appropriate manner to provide clear, defensible data for multi-jurisdictional IND and IMPD submissions.
Core Analytical Capabilities for Toxicology Support
A comprehensive analytical strategy for IND-enabling studies must address multiple facets of the vector’s behavior in vivo. This extends beyond simple titer and purity measurements of the initial drug product.
-
Biodistribution & Shedding: Quantitative PCR (qPCR) and droplet digital PCR (ddPCR) assays are developed to measure vector genome distribution in tissues and potential shedding in excreta. This data informs non-target tissue biodistribution assessments.
-
Transgene Expression: Methods like RT-qPCR, ELISA, or Western Blot are used to confirm and quantify transgene expression in target tissues, linking biodistribution to functional activity.
-
Immunogenicity: High-resolution immune profiling and neutralizing antibody (NAb) assays determine the host immune response to the vector capsid and transgene product, a key safety consideration.
-
Histology & Pathology Support: Analytical data is correlated with findings from board-certified veterinary pathologists to build a complete safety narrative.
Our work is conducted within a 100,000+ sq ft facility designed to integrate vector production, analytics, and in vivo studies. This co-location of expertise ensures that analytical methods are developed with a direct line of sight to the complexities of the biological system being tested. This integrated approach is part of a broader commitment to animal welfare, including adherence to the 3Rs (Replacement, Reduction, and Refinement) and AAALAC/USDA guidelines.
For a complete overview of our capabilities, please see our parent hub page on Vector | CMC | Analytics Services.
Featured Video: RESPONSIBILITY AND ANIMAL WELFARE
This video details Franklin Biolabs’ commitment to animal care and welfare, highlighting our adherence to international guidelines and the three Rs (Reduce, Refine, Replace) of animal research.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.